Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Mcgranahan, A. Furness, R. Rosenthal, S. Ramskov, R. Lyngaa, S. Saini, M. Jamal-Hanjani, G. Wilson, N. Birkbak, C. Hiley, T. Watkins, S. Shafi, N. Murugaesu, R. Mitter, A. Akarca, J. Linares, T. Marafioti, J. Henry, E. Allen, Diana Miao, B. Schilling, D. Schadendorf, L. Garraway, V. Makarov, N. Rizvi, A. Snyder, M. Hellmann, T. Merghoub, J. Wolchok, S. Shukla, Catherine Wu, K. Peggs, T. Chan, S. Hadrup, S. Quezada, C. Swanton (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience, 351
J. Strickler, B. Hanks, M. Khasraw (2020)
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Clinical Cancer Research, 27
Ö. Türeci, M. Vormehr, M. Diken, S. Kreiter, C. Huber, U. Şahin (2016)
Targeting the Heterogeneity of Cancer with Individualized Neoepitope VaccinesClinical Cancer Research, 22
C. Valero, Mark Lee, Douglas Hoen, A. Zehir, M. Berger, V. Seshan, T. Chan, L. Morris (2021)
Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.JAMA oncology
G. Long, R. Dummer, O. Hamid, T. Gajewski, C. Caglevic, S. Dalle, A. Arance, M. Carlino, J. Grob, T. Kim, L. Demidov, C. Robert, J. Larkin, James Anderson, J. Maleski, Mark Jones, S. Diede, T. Mitchell (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.The Lancet. Oncology
H. Schildhaus (2018)
Der prädiktive Wert der PD-L1-DiagnostikDer Pathologe, 39
J. Marin-Acevedo, E. Kimbrough, Y. Lou (2021)
Next generation of immune checkpoint inhibitors and beyondJournal of Hematology & Oncology, 14
M. Tsao, K. Kerr, M. Kockx, M. Beasley, A. Borczuk, J. Botling, L. Bubendorf, L. Chirieac, Gang Chen, T. Chou, Jin-Haeng Chung, S. Dacic, S. Lantuejoul, M. Mino‐Kenudson, A. Moreira, A. Nicholson, M. Noguchi, G. Pelosi, C. Poleri, P. Russell, J. Sauter, E. Thunnissen, I. Wistuba, Hui Yu, M. Wynes, M. Pintilie, Y. Yatabe, F. Hirsch (2018)
PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 13
M. Wojtukiewicz, Magdalena Rek, Kamil Karpowicz, M. Górska, B. Politynska, Anna Wojtukiewicz, M. Moniuszko, P. Radziwon, S. Tucker, K. Honn (2021)
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitionersCancer Metastasis Reviews, 40
B. Helmink, S. Reddy, Jianjun Gao, Shaojun Zhang, R. Başar, R. Thakur, Keren Yizhak, Moshe Sade-Feldman, J. Blando, Guangchun Han, V. Gopalakrishnan, Y. Xi, Hao Zhao, R. Amaria, H. Tawbi, Alexandria Cogdill, Wenbin Liu, Valerie LeBleu, Fernanda Kugeratski, S. Patel, M. Davies, P. Hwu, Jeffrey Lee, J. Gershenwald, A. Lucci, R. Arora, S. Woodman, E. Keung, P. Gaudreau, A. Reuben, C. Spencer, E. Burton, L. Haydu, A. Lazar, Roberta Zapassodi, C. Hudgens, D. Ledesma, Sufey Ong, M. Bailey, S. Warren, Disha Rao, O. Krijgsman, E. Rozeman, D. Peeper, C. Blank, T. Schumacher, L. Butterfield, M. Zelazowska, Kevin McBride, R. Kalluri, J. Allison, F. Petitprez, W. Fridman, C. Sautès-Fridman, N. Hacohen, K. Rezvani, P. Sharma, M. Tetzlaff, Linghua Wang, J. Wargo (2020)
B cells and tertiary lymphoid structures promote immunotherapy responseNature, 577
H. Yamaguchi, J. Hsu, Wen-Hao Yang, M. Hung (2022)
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeuticsNature Reviews Clinical Oncology, 19
Douglas Johnson, C. Nebhan, J. Moslehi, J. Balko (2022)
Immune-checkpoint inhibitors: long-term implications of toxicityNature Reviews. Clinical Oncology, 19
B. Burtness, K. Harrington, R. Greil, D. Soulières, M. Tahara, G. Castro, A. Psyrri, N. Basté, P. Neupane, A. Bratland, T. Fuereder, B. Hughes, R. Mesía, N. Ngamphaiboon, T. Rordorf, W. Ishak, R. Hong, R. Mendoza, A. Roy, Yayan Zhang, B. Gumuscu, Jonathan Cheng, F. Jin, D. Rischin, G. Lerzo, M. Tatangelo, M. Varela, J. Zarbá, M. Boyer, H. Gan, Bo Gao, B. Hughes, G. Mallesara, Anne Taylor, M. Burian, C. Barrios, D. Junior, G. Castro, F. Franke, G. Girotto, I. Lima, U. Nicolau, G. Pinto, L. Santos, A. Victorino, N. Chua, F. Couture, R. Gregg, A. Hansen, J. Hilton, J. McCarthy, D. Soulières, R. Ascui, P. González, L. Villanueva, Marco Torregroza, A. Zambrano, P. Holečková, Z. Král, B. Melichar, J. Prausová, M. Vošmik, M. Andersen, N. Gyldenkerne, H. Jurgens, Kadri Putnik, P. Reinikainen, V. Gruenwald, S. Laban, G. Aravantinos, I. Boukovinas, V. Georgoulias, D. Kwong, Y. Al-farhat, T. Csőszi, J. Erfán, G. Horvai, L. Landherr, É. Remenár, Á. Ruzsa, J. Szota, S. Billan, I. Gluck, O. Gutfeld, A. Popovtzer, M. Benasso, S. Bui, V. Ferrari, L. Licitra, F. Nolè, T. Fujii, Y. Fujimoto, N. Hanai, H. Hara, Koji Matsumoto, K. Mitsugi, N. Monden, M. Nakayama, K. Okami, N. Oridate, K. Shiga, Y. Shimizu, M. Sugasawa, Masanobu Takahashi, S. Takahashi, Kaoru Tanaka, T. Ueda, H. Yamaguchi, T. Yamazaki, R. Yasumatsu, T. Yokota, T. Yoshizaki, I. Kudaba, Zinaida Stara, S. Cheah, J. Ponce, R. Mendoza, C. Hernández, F. Soto, J. Buter, A. Hoeben, S. Oosting, K. Suijkerbuijk, A. Bratland, Marianne Brydoey, R. Alvarez, L. Mas, P. Caguioa, J. Querol, E. Regala, Maria Tamayo, Ellie Villegas, A. Kawecki, A. Karpenko, A. Klochikhin, A. Smolin, O. Zarubenkov, B. Goh, G. Cohen, J. Toit, Christa Jordaan, G. Landers, P. Ruff, W. Szpak, N. Tabane, I. Braña, L. Docampo, J. Lavernia, R. Mesía, Edvard Abel, Valentina Muratidu, Niels Nielsen, V. Cristina, S. Rothschild, Hung-Ming Wang, Muh-Hwa Yang, S. Yeh, C. Yen, N. Soparattanapaisarn, V. Sriuranpong, S. Aksoy, I. Çiçin, M. Ekenel, H. Harputluoglu, O. Ozyılkan, K. Harrington, S. Agarwala, H. Ali, R. Alter, Daniel Anderson, J. Bruce, N. Campbell, M. Conde, J. Deeken, W. Edenfield, L. Feldman, Elizabeth Gaughan, B. Goueli, B. Halmos, U. Hegde, B. Hunis, R. Jotte, A. Karnad, Saad Khan, N. Laudi, D. Laux, D. Martincic, S. McCune, D. Mcgaughey, K. Misiukiewicz, D. Mulford, E. Nadler, J. Nunnink, J. Ohr, M. O’Malley, B. Patson, D. Paul, E. Popa, S. Powell, R. Redman, V. Rella, Chaio Lima, A. Sivapiragasam, Y. Su, A. Sukari, Stuart Wong, E. Yilmaz, J. Yorio (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 394
L. Alexandrov, S. Nik-Zainal, D. Wedge, S. Aparicio, S. Behjati, A. Biankin, G. Bignell, N. Bolli, Å. Borg, A. Børresen-Dale, S. Boyault, B. Burkhardt, A. Butler, C. Caldas, H. Davies, C. Desmedt, R. Eils, J. Eyfjörd, J. Foekens, M. Greaves, F. Hosoda, B. Hutter, Tomislav Ilicic, S. Imbeaud, Marcin Imielinsk, N. Jäger, David Jones, David Jones, S. Knappskog, M. Kool, S. Lakhani, C. López-Otín, Sancha Martin, N. Munshi, Hiromi Nakamura, P. Northcott, M. Pajic, E. Papaemmanuil, A. Paradiso, J. Pearson, X. Puente, K. Raine, Manasa Ramakrishna, A. Richardson, J. Richter, P. Rosenstiel, M. Schlesner, T. Schumacher, P. Span, J. Teague, Y. Totoki, A. Tutt, R. Valdés-Mas, Marit Buuren, L. Veer, A. Vincent-Salomon, N. Waddell, L. Yates, J. Zucman‐Rossi, P. Futreal, U. McDermott, P. Lichter, M. Meyerson, S. Grimmond, R. Siebert, E. Campo, T. Shibata, S. Pfister, P. Campbell, M. Stratton (2013)
Signatures of mutational processes in human cancerNature, 500
Merav Cohen, Amir Giladi, Oren Barboy, Pauline Hamon, Baoguo Li, M. Zada, A. Gurevich-Shapiro, C. Beccaria, Eyal David, B. Maier, Mark Buckup, I. Kamer, A. Deczkowska, Jessica Berichel, J. Bar, M. Iannacone, A. Tanay, M. Merad, I. Amit (2022)
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade responseNature Cancer, 3
T. Gide, C. Quek, A. Menzies, Annie Tasker, Ping Shang, J. Holst, J. Madore, S. Lim, R. Velickovic, M. Wongchenko, Yibing Yan, S. Lo, M. Carlino, A. Guminski, R. Saw, A. Pang, H. McGuire, U. Palendira, J. Thompson, H. Rizos, I. Silva, M. Batten, R. Scolyer, G. Long, J. Wilmott (2019)
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.Cancer cell, 35 2
V. Anagnostou, Kellie Smith, P. Forde, N. Niknafs, Rohit Bhattacharya, J. White, Theresa Zhang, V. Adleff, J. Phallen, N. Wali, C. Hruban, V. Guthrie, Kristen Rodgers, J. Naidoo, Hyunseok Kang, W. Sharfman, C. Georgiades, Franco Verde, P. Illei, Q. Li, E. Gabrielson, M. Brock, C. Zahnow, S. Baylin, R. Scharpf, J. Brahmer, R. Karchin, D. Pardoll, V. Velculescu (2017)
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.Cancer discovery, 7 3
B. Rini, E. Plimack, V. Stus, R. Gafanov, R. Hawkins, D. Nosov, F. Pouliot, B. Alekseev, D. Soulières, B. Melichar, I. Vynnychenko, A. Kryzhanivska, I. Bondarenko, S. Azevedo, D. Borchiellini, C. Szczylik, M. Markus, R. McDermott, J. Bedke, S. Tartas, Yen‐Hwa Chang, S. Tamada, Q. Shou, R. Perini, Mei Chen, M. Atkins, T. Powles (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell CarcinomaThe New England Journal of Medicine, 380
Heidi Ledford (2011)
Melanoma drug wins US approvalNature, 471
Ivelina Spassova, S. Ugurel, Linda Kubat, L. Zimmer, P. Terheyden, Ann-Katrin Mohr, Hannah Andtback, L. Villabona, U. Leiter, T. Eigentler, C. Loquai, J. Hassel, T. Gambichler, S. Haferkamp, P. Mohr, C. Pfoehler, L. Heinzerling, R. Gutzmer, J. Utikal, K. Horny, H. Schildhaus, Daniel Habermann, Daniel Hoffmann, D. Schadendorf, J. Becker (2022)
Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinomaJournal for Immunotherapy of Cancer, 10
H. Zander, S. Müller-Egert, M. Zwiewka, S. Groß, G. Zandbergen, J. Engelbergs (2020)
Checkpointinhibitoren in der TumortherapieBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63
Pin Wu, Dang Wu, Lijun Li, Y. Chai, Jian Huang (2015)
PD-L1 and Survival in Solid Tumors: A Meta-AnalysisPLoS ONE, 10
E. Cohen, D. Soulières, C. Tourneau, J. Dinis, L. Licitra, M. Ahn, A. Soria, J. Machiels, N. Mach, R. Mehra, B. Burtness, Pingye Zhang, Jonathan Cheng, R. Swaby, K. Harrington, M. Acosta-Rivera, D. Adkins, M. Aghmesheh, M. Airoldi, E. Aleknavičius, Y. Al-farhat, A. Algazi, S. Almokadem, A. Alyasova, J. Bauman, M. Benasso, A. Berrocal, V. Bray, B. Burtness, F. Caponigro, A. Castro, T. Cescon, Kelvin Chan, A. Chaudhry, B. Chauffert, E. Cohen, T. Csőszi, J. Boer, J. Delord, A. Dietz, J. Dinis, C. Dupuis, L. Digue, J. Erfán, Y. Álvarez, M. Evans, M. Fidler, M. Forster, S. Friesland, A. Ganti, L. Geoffrois, C. Grant, V. Gruenwald, K. Harrington, T. Hoffmann, G. Horvai, A. Inčiūra, R. Jang, P. Jankowska, A. Jimeno, M. Joseph, A. Ramiro, B. Karaszewska, A. Kawecki, U. Keilholz, U. Keller, Sung-Bae Kim, J. Kocsis, N. Kotecki, M. Kozloff, J. Lambea, L. Landherr, Yuri Lantsukhay, S. Lazarev, Lip Lee, Igor Lifirenko, D. Martincic, O. Matorin, M. McGrath, K. Misiukiewicz, J. Morris, F. Mufazalov, J. Niu, D. Srinivasan, P. Segura, D. Rauch, Maria Ribeiro, C. Rodriguez, F. Rolland, A. Russo, Á. Ruzsa, Frederico Sanches, S. Shin, Mikhail Shtiveland, D. Soulières, P. Specenier, É. Szekanecz, J. Szota, C. Herpen, Hector Velez-Cortes, W. Walsh, S. Wilop, R. Winterhalder, M. Wojtukiewicz, D. Wong, D. Zandberg (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyThe Lancet, 393
Yan Li, Qin Huang, Yaoyao Zhou, Meizhi He, Jianhong Chen, Yubo Gao, Xue Wang (2019)
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-AnalysisFrontiers in Pharmacology, 9
Pramod Darvin, S. Toor, V. Nair, E. Elkord (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkersExperimental & Molecular Medicine, 50
I. Vitale, E. Shema, S. Loi, L. Galluzzi (2021)
Intratumoral heterogeneity in cancer progression and response to immunotherapyNature Medicine, 27
D. Gandara, S. Paul, M. Kowanetz, E. Schleifman, W. Zou, Yan Li, A. Rittmeyer, L. Fehrenbacher, G. Otto, C. Malboeuf, Daniel Lieber, D. Lipson, J. Silterra, L. Amler, T. Riehl, C. Cummings, P. Hegde, A. Sandler, M. Ballinger, D. Fabrizio, T. Mok, D. Shames (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabNature Medicine, 24
Florence Koeppel, S. Blanchard, C. Jovelet, B. Génin, C. Marcaillou, Emmanuel Martin, E. Rouleau, E. Solary, J. Soria, F. André, L. Lacroix (2017)
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patientsPLoS ONE, 12
Daniel Wang, J. Salem, J. Cohen, S. Chandra, C. Menzer, Fei Ye, Shilin Zhao, Satya Das, K. Beckermann, Lisa Ha, W. Rathmell, K. Ancell, J. Balko, C. Bowman, E. Davis, D. Chism, L. Horn, G. Long, M. Carlino, B. Lebrun-Vignes, Z. Eroglu, J. Hassel, A. Menzies, J. Sosman, R. Sullivan, J. Moslehi, Douglas Johnson (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisJAMA Oncology, 4
R. Motzer, B. Alekseev, S. Rha, C. Porta, M. Eto, T. Powles, V. Grünwald, Thomas Hutson, E. Kopyltsov, M. Méndez-Vidal, V. Kozlov, A. Alyasova, Sung-Hoo Hong, A. Kapoor, T. Gordoa, J. Merchan, E. Winquist, P. Maroto, J. Goh, Miso Kim, H. Gurney, V. Patel, A. Peer, G. Procopio, T. Takagi, B. Melichar, F. Rolland, U. Giorgi, Shirley Wong, J. Bedke, M. Schmidinger, C. Dutcus, Alan Smith, L. Dutta, K. Mody, R. Perini, D. Xing, T. Choueiri (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.The New England journal of medicine
R. Büttner, J. Longshore, F. López-Rios, S. Merkelbach-Bruse, N. Normanno, E. Rouleau, F. Penault-Llorca (2019)
Implementing TMB measurement in clinical practice: considerations on assay requirementsESMO Open, 4
R. Huss, C. Schmid, Mael Manesse, J. Thagaard, B. Maerkl (2021)
Immunological tumor heterogeneity and diagnostic profiling for advanced and immune therapiesAdvances in Cell and Gene Therapy, 4
Xuewen Wang, Shijie Wu, Yaying Chen, Erqian Shao, Tingting Zhuang, Linbin Lu, Xiong Chen (2020)
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-AnalysisFrontiers in Pharmacology, 11
E. Brozos-Vázquez, R. Díaz-Peña, J. García-González, L. León-Mateos, P. Mondelo-Macía, M. Peña-Chilet, R. López-López (2020)
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsyCancer Immunology, Immunotherapy, 70
A. Marabelle, M. Fakih, Juanita Lopez, M. Shah, R. Shapira-Frommer, K. Nakagawa, H. Chung, H. Kindler, J. López-Martín, W. Miller, A. Italiano, S. Kao, S. Piha-Paul, J. Delord, R. McWilliams, D. Fabrizio, D. Aurora-Garg, Lei Xu, F. Jin, K. Norwood, Y. Bang (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.The Lancet. Oncology
C. Blank, J. Haanen, A. Ribas, T. Schumacher (2016)
The “cancer immunogram”Science, 352
R. Corcoran, B. Chabner (2018)
Application of Cell-free DNA Analysis to Cancer Treatment.Obstetrical & Gynecological Survey
Xiaoxue Ma, Zhoubo Guo, Xiaoying Wei, Gang Zhao, Dong Han, Tian Zhang, Xi Chen, F. Cao, Jie Dong, Lujun Zhao, Z. Yuan, Ping Wang, Q. Pang, Cihui Yan, Wencheng Zhang (2022)
Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 BlockadeFrontiers in Immunology, 12
F. Fenizia, R. Pasquale, C. Roma, F. Bergantino, Alessia Iannaccone, N. Normanno (2018)
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy.Translational lung cancer research, 7 6
Mihaela Angelova, B. Mlecnik, A. Vasaturo, G. Bindea, T. Fredriksen, Lucie Lafontaine, Bénédicte Buttard, Erwan Morgand, Daniela Bruni, A. Jouret-Mourin, C. Hubert, A. Kartheuser, Y. Humblet, M. Ceccarelli, Najeeb Syed, F. Marincola, D. Bedognetti, M. Eynde, J. Galon (2018)
Evolution of Metastases in Space and Time under Immune SelectionCell, 175
T. Choueiri, T. Powles, M. Burotto, B. Escudier, M. Bourlon, B. Żurawski, Victor Juárez, J. Hsieh, U. Basso, A. Shah, C. Suarez, A. Hamzaj, J. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, Juan Feregrino, J. Zolnierek, D. Pook, E. Kessler, Y. Tomita, R. Mizuno, J. Bedke, Joshua Zhang, M. Maurer, B. Simsek, F. Ejzykowicz, G. Schwab, A. Apolo, R. Motzer (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.The New England journal of medicine, 384 9
Rita Cabrita, M. Lauss, Adriana Sanna, M. Donia, Mathilde Larsen, Shamik Mitra, I. Johansson, Bengt Phung, K. Harbst, J. Vallon-Christersson, Alison Schoiack, Kristina Lövgren, S. Warren, K. Jirström, H. Olsson, K. Pietras, C. Ingvar, K. Isaksson, D. Schadendorf, H. Schmidt, L. Bastholt, A. Carneiro, J. Wargo, I. Svane, G. Jönsson (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanomaNature, 577
S. Topalian, C. Drake, D. Pardoll (2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer cell, 27 4
Steve Lu, Julie Stein, D. Rimm, Daphne Wang, J. Bell, Douglas Johnson, J. Sosman, K. Schalper, R. Anders, Hao Wang, C. Hoyt, D. Pardoll, Ludmila Danilova, J. Taube (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.JAMA oncology
Francesco Logu, F. Galli, R. Nassini, Filippo Ugolini, Sara Simi, M. Cossa, C. Miracco, A. Gianatti, V. Giorgi, E. Rulli, A. Cossu, D. Massi, M. Mandalà (2021)
Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma PatientsCells, 10
Corcoran (2018)
Application of cell-free dna analysis to cancer treatmentN Engl J Med, 379
T. Powles, Z. Assaf, N. Davarpanah, R. Banchereau, B. Szabados, K. Yuen, P. Grivas, M. Hussain, S. Oudard, J. Gschwend, P. Albers, D. Castellano, H. Nishiyama, S. Daneshmand, Shruti Sharma, B. Zimmermann, H. Sethi, A. Aleshin, M. Perdicchio, Jingbin Zhang, D. Shames, V. Degaonkar, Xiao-dong Shen, Corey Carter, C. Bais, J. Bellmunt, S. Mariathasan (2021)
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaNature, 595
Immune-checkpoint-inhibitor (ICI) therapy has been one of the major advances in the treatment of a variety of advanced or metastatic tumors in recent years. Therefore, ICI-therapy is already approved in first-line therapy for multiple tumors, either as monotherapy or as combination therapy. However, there are relevant differences in approval among different tumor entities, especially with respect to PD-L1 testing. Different response to ICI-therapy has been observed in the pivotal trials, so PD-L1 diagnostic testing is used for patient selection. In addition to PD-L1 testing of tumor tissue, liquid biopsy provides a noninvasive way to monitor disease in cancer patients and identify those who would benefit most from ICI-therapy. This overview focuses on the use of ICI-therapy and how it relates to common and potential future biomarkers for patient-directed treatment planning.
Advances in Anatomic Pathology – Wolters Kluwer Health
Published: May 3, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.